Safety and efficacy of selective RIPK1 inhibitor SIR1-365 in hospitalized patients with severe COVID-19: A multicenter, randomized, double-blind, phase 1b trial
SIR1-365 was well tolerated and demonstrated a trend toward quicker recovery than placebo in hospitalized patients with severe COVID-19.<b>Trial Registration</b> ClinicalTrials.gov number: NCT04622332.
Authors
- Muneeba Ahsan Sayeed (ORCID: https://orcid.org/0000-0003-4971-295X)
- Weiliang Fan (ORCID: https://orcid.org/0000-0003-2030-7168)
- Bin Du (ORCID: https://orcid.org/0000-0001-6237-2895)
- Norberto C. Chávez‐Tapia (ORCID: https://orcid.org/0000-0002-7451-3306)
- Yang Shen (ORCID: https://orcid.org/0009-0000-9978-0315)
- Wei Yuan (ORCID: https://orcid.org/0000-0002-6866-4474)
- Douglas J Kasper
- Shobha Luxmi (ORCID: https://orcid.org/0000-0002-0117-3048)
- Fenchao Xue
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- OSF Saint Francis Medical Center (US)
- Dow University of Health Sciences (PK)
- OSF HealthCare (US)
- Hospital Médica Sur (MX)
- Washington Poison Center (US)
Publication Details
- Journal
- Journal of Intensive Medicine
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1016/j.jointm.2024.07.003
- Citations
- 9
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 2.16